Lake Street Capital Cuts Evaxion Biotech A/S (NASDAQ:EVAX) Price Target to $6.00

Evaxion Biotech A/S (NASDAQ:EVAX) had its price objective cut by Lake Street Capital from $35.00 to $6.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a report on Monday.

Evaxion Biotech A/S Stock Performance

Shares of Evaxion Biotech A/S stock opened at $2.75 on Tuesday. The business’s 50 day moving average price is $4.59 and its 200 day moving average price is $10.48. The company has a market cap of $3.22 million, a price-to-earnings ratio of -1.90 and a beta of -0.28. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a one year low of $2.22 and a one year high of $23.70.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.